November 21, 2011
Drugmakers Novartis AG and Mylan Inc. have settled patent litigation over Mylan's bid to produce a generic version of Novartis' estrogen therapy drug Vivelle-Dot, which will allow the generic to be manufactured, Mylan announced Monday.